Conference call to be held today at 10:00 AM Eastern Time
VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ – ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”), today reported financial results for the 2025 second quarter ended June 30, 2025. The financial statements and MD&A are available on SEDAR under the Company’s profile.
“The second quarter marked steady progress in our transformation journey,” commented Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. “Despite continued macroeconomic pressures and funding constraints, we streamlined operations, advanced regulatory momentum, and continued to build a pipeline for long-term sustainable growth.”
“We are especially encouraged by the regulatory developments in the United States, including Operation Stork Speed, the FY2026 Agriculture Appropriations Bill, and recommendations from the National Academies of Sciences, Engineering, and Medicine. Together, these signal a clearer pathway for modernizing infant formula standards and give us increased confidence in advancing our plant-based infant formula clinical trials.”
“From a financial standpoint, revenue was impacted by temporary inventory constraints and out-of-stocks, however, demand for our products remains strong and production is now underway with expected availability next month. As a result, our gross profit was temporarily negative this quarter. It is important to note that late 2024 deductions totaling approximately CAD $270 thousand in the U.S. and Canada reduced both revenue and gross profit, though these were not reflective of Q2’s operating performance. With our planned transition to European-based powder production, and continued supply chain optimization, including the restructuring …